Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Yixie Zhang, Ashley Bonner, Matthew Lunning

Blood (2024) 144 (Supplement 1): 3130.

https://doi.org/10.1182/blood-2024-200937

Published: 2024

Journal Articles

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lara Stepan, Sahar Ansari, Abood Okal, Justine Dell'Aringa, Ethan Thompson, Alessandro Crotta, Victor A Chow, Jeremy S. Abramson, Manali Kamdar, Jacob J. Chabon, Gregory Hogan, David M. Kurtz, Ash A. Alizadeh, Leanne Peiser

Blood (2023) 142 (Supplement 1): 225.

https://doi.org/10.1182/blood-2023-181007

Published: 2023

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar

Blood (2022) 140 (Supplement 1): 1581–1583.

https://doi.org/10.1182/blood-2022-159702

Published: 2022

Journal Articles

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Jeremy S. Abramson, Manali Kamdar, Fei Fei Liu, Alessandro Crotta, Alessandro Previtali, Sven L. Klijn, Pearl Wang, Aaron Situ, Yixie Zhang, Ashley Bonner, Matthew A. Lunning

Blood (2022) 140 (Supplement 1): 4655–4656.

https://doi.org/10.1182/blood-2022-160216

Published: 2022

Journal Articles

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Nilanjan Ghosh, Alison R. Sehgal, Fei Fei Liu, Ana Kostic, Alessandro Crotta, Lily Peng, Marc De Benedetti, Leo I. Gordon

Blood (2022) 140 (Supplement 1): 10430–10431.

https://doi.org/10.1182/blood-2022-159686

Published: 2022

Journal Articles

Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Results from the Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Fei Fei Liu, Julia Braverman, Shien Guo, Ling Shi, Manali Kamdar

Blood (2021) 138 (Supplement 1): 3845.

https://doi.org/10.1182/blood-2021-151611

Published: 2021

Journal Articles

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Blood (2021) 138 (Supplement 1): 91.

https://doi.org/10.1182/blood-2021-147913

Published: 2021

Journal Articles

Pharmacokinetics (PK) Study Of Antithymocyte Globulins Fresenius (ATG-F) Prior To Allogeneic Stem Cell Transplantation: Implications For Timing Of Graft and Early Adoptive Immunotherapy Infusions

Sara Mastaglio, MD, Alessandra Forcina, MD, Isabell Seitz, Holger Martinius, Jacopo Peccatori, MD, Massimo Bernardi, MD, Daniela Clerici, MD, Consuelo Corti, MD, Alessandro Crotta, MD, Maria Teresa Lupo Stanghellini, MD, Carlo Messina, MD, Chiara Bonini, MD, Fabio Ciceri

Blood (2013) 122 (21): 4536.

https://doi.org/10.1182/blood.V122.21.4536.4536

Published: 2013

Journal Articles

Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study

Blood (2013) 122 (12): 2135–2141.

https://doi.org/10.1182/blood-2013-03-491589

Published: 2013

Journal Articles

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Blood (2013) 121 (6): 1059–1064.

https://doi.org/10.1182/blood-2012-07-445965

Published: 2013

Includes: Supplemental data

Journal Articles

Intensive Treatment in Elderly AML Patients Induce Prolonged Survival and Disease Remission If Early Mortality Is Prevented: The Case Record of the San Raffaele Scientific Institute

Massimo Bernardi, MD, Matteo Carrabba, MD, Michela Tassara, MD, Carlo Messina, MD, Alessandro Crotta, MD, Elisa Sala, MD, Alessandro Vignati, Elena Guggiari, MD, Raffaella Greco, MD, Luca vago, MD, Bernhard Gentner, MD, Simona Piemontese, MD, Andrea Assanelli, MD, Jacopo Peccatori, MD, Consuelo Corti, MD, Fabio Ciceri, MD

Blood (2011) 118 (21): 4583.

https://doi.org/10.1182/blood.V118.21.4583.4583

Published: 2011

Journal Articles

Monitoring of Wilms' Tumor Gene 1 Levels Predict Early Relapse After Allogeneic Hematopoietic Stem Cells Transplantation in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome,

Elisa Sala, MD, Carlo Messina, MD, Cristina Tresoldi, Matteo Carrabba, MD, Michela Tassara, MD, Alessandro Crotta, MD, Alessandro Vignati, Elena Guggiari, MD, Roberta Mattarucchi, Andrea Assanelli, MD, Jacopo Peccatori, MD, Consuelo Corti, MD, Fabio Ciceri, MD, Massimo Bernardi, MD

Blood (2011) 118 (21): 4102.

https://doi.org/10.1182/blood.V118.21.4102.4102

Published: 2011

Journal Articles

Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution

Blood (2010) 116 (21): 2385.

https://doi.org/10.1182/blood.V116.21.2385.2385

Published: 2010

Journal Articles

Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT

Alessandro Crotta, MD, Gerard Michel, MD, Guillermo F. Sanz, MD, PhD, Gerard Socie, Tracey A. O'Brien, MD, William Arcese, MD, Didier Blaise, MD, Yves Bertrand, MD, Miguel A. Diaz, MD, Ajay J. Vora, MD, FRCP, FRCPath, Franca Fagioli, MD, Giorgio Dini, MD, Jean-Hugues Dalle, Mohamad Mohty, Myriam Labopin, MD, Eliane Gluckman, MD, André Tichelli, MD, Vanderson Rocha, MD, PhD

Blood (2010) 116 (21): 219.

https://doi.org/10.1182/blood.V116.21.219.219

Published: 2010

Journal Articles

Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Cord Blood Transplantation (CBT). Retrospective Analysis on Behalf of Eurocord and the EBMT Autoimmune Diseases Working Party.

Blood (2010) 116 (21): 3460.

https://doi.org/10.1182/blood.V116.21.3460.3460

Published: 2010

Journal Articles

Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study

Blood (2010) 116 (21): 533.

https://doi.org/10.1182/blood.V116.21.533.533

Published: 2010

Journal Articles

Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study

Vanderson Rocha, MD, PhD, Myriam Labopin, MD, Mohamad Mohty, Guillermo F Sanz, MD, PhD, Bernard Rio, MD, Sabine Furst, Anne Sirvent, MD, Gérard Socié, Reza Tabrizzi, Ibrahim Yakoubagha, Eric Deconinck, Jan J. Cornelissen, MD, PhD, William Arcese, MD, Josep-Maria Ribera, MD, PhD, E. Nikiforakis, Mauricette Michallet, Alessandro Crotta, MD, Annalisa Ruggeri, MD, Eliane Gluckman, MD

Blood (2010) 116 (21): 910.

https://doi.org/10.1182/blood.V116.21.910.910

Published: 2010

Journal Articles

Viral Infection After Unrelated Cord Blood Transplantation In Bordeaux: Incidence and Outcomes. A Single Centre Experience with Eurocord.

Pierre-Yves Dumas, Reza Tabrizi, Stephane Vigouroux, Marie-Edith Lafon, Gerald Marit, Arnaud Pigneux, Thibaut Leguay, Krimo Bouabdallah, Marie-Sarah Dilhuydy, Axelle Lascaux, Anna Schmitt, Alessandro Crotta, Vanderson Rocha, Noel-Jean Milpied

Blood (2010) 116 (21): 4543.

https://doi.org/10.1182/blood.V116.21.4543.4543

Published: 2010

NARROW

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up

Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Pharmacokinetics (PK) Study Of Antithymocyte Globulins Fresenius (ATG-F) Prior To Allogeneic Stem Cell Transplantation: Implications For Timing Of Graft and Early Adoptive Immunotherapy Infusions

Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study

New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation

Intensive Treatment in Elderly AML Patients Induce Prolonged Survival and Disease Remission If Early Mortality Is Prevented: The Case Record of the San Raffaele Scientific Institute

Monitoring of Wilms' Tumor Gene 1 Levels Predict Early Relapse After Allogeneic Hematopoietic Stem Cells Transplantation in Patients with High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome,

Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution

Incidence and Risk Factors of Chronic Graft-Versus-Host Disease After Unrelated Cord Blood Transplant In Children and Adults. A Retrospective Study on Behalf of EUROCORD and Late-Effect Working Party of EBMT

Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Cord Blood Transplantation (CBT). Retrospective Analysis on Behalf of Eurocord and the EBMT Autoimmune Diseases Working Party.

Analysis of Risk Factors Influencing Outcomes After Unrelated Cord Blood Transplantation In Children with Juvenile Myelomonocytic Leukemia. An Eurocord, EBMT, EWOG-MDS, CIBMTR Study

Outcomes After Double Unit Unrelated Cord Blood Transplantation (UCBT) Compared with Single UCBT In Adults with Acute Leukemia In Remission. An Eurocord and ALWP Collaboration Study

Viral Infection After Unrelated Cord Blood Transplantation In Bordeaux: Incidence and Outcomes. A Single Centre Experience with Eurocord.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only